Jacobs Levy Equity Management, Inc Biomarin Pharmaceutical Inc Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 52,071 shares of BMRN stock, worth $3.47 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
52,071Holding current value
$3.47 Million% of portfolio
0.01%Shares
12 transactions
Others Institutions Holding BMRN
# of Institutions
637Shares Held
177MCall Options Held
2.01MPut Options Held
1.28M-
Black Rock Inc. New York, NY22.7MShares$1.52 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.3MShares$1.28 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.9MShares$1.26 Billion0.99% of portfolio
-
Dodge & Cox San Francisco, CA13.9MShares$926 Million0.59% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.5MShares$699 Million0.16% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $12.4B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...